Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative

Reuters

09/24

Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative

**Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2569706251"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569706251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569706251?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569706251","market":"fut","top_or_hot":-1,"title":"Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-24 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL2TpW3:1","article_id":"2569706251","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569706251","pubTimestamp":1758715216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire  on September 24, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","DARE":"Dare Bioscience","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4584":"避孕概念","BK4007":"制药","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"DaréBioscience获得盖茨基金会高达499,000美元的资助，以支持全球先兆子痫研究；将指导大挑战计划下的多个组织","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"DARE":0.9},"content_text":"Daré Bioscience Secures Up to $499,000 Gates Foundation Grant to Support Global Preeclampsia Research; Will Mentor Multiple Organizations Under Grand Challenges Initiative\n    \n\n        **Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}